Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

First patient receives BCX7353 dosing in BioCryst’s Phase II trial for HAE

Go Top